Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
about
Possible drug-drug interaction in dogs and cats resulted from alteration in drug metabolism: A mini reviewAssessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.An update on computational oral absorption simulation.Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development.Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?Use of physiologically based pharmacokinetic modeling for assessment of drug-drug interactions.Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach.Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling.Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.The Prediction of the Relative Importance of CYP3A/P-glycoprotein to the Nonlinear Intestinal Absorption of Drugs by Advanced Compartmental Absorption and Transit Model.Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse events.Maximizing the outcome of early ADMET models: strategies to win the drug-hunting battles?Randomised controlled trial of two sequential artemisinin-based combination therapy regimens to treat uncomplicated falciparum malaria in African children: a protocol to investigate safety, efficacy and adherence.Effects of artemisinin antimalarials on Cytochrome P450 enzymes in vitro using recombinant enzymes and human liver microsomes: potential implications for combination therapies.Influence of covariance between random effects in design for nonlinear mixed-effect models with an illustration in pediatric pharmacokinetics.Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model.Minimal Physiologically Based Pharmacokinetic and Drug-Drug-Disease Interaction Model of Rivaroxaban and Verapamil in Healthy and Renally Impaired Subjects.Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling.Investigation of an alternative generic model for predicting pharmacokinetic changes during physiological stress.A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.Quantitative prediction of the extent of drug-drug interaction using a physiologically based pharmacokinetic model that includes inhibition of drug metabolism determined in cryopreserved hepatocytes.Unbound liver concentration is the true inhibitor concentration that determines cytochrome P450-mediated drug-drug interactions in rat liver.Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment.Semimechanistic Population Pharmacokinetic Model to Predict the Drug-Drug Interaction Between S-ketamine and Ticlopidine in Healthy Human Volunteers
P2860
Q26800015-B37173F0-E87A-45DC-9943-D88C69C4DA90Q34476096-8BB6166F-4C95-4363-B133-1CBBF6F59162Q37937047-6DB4F288-FBD3-4FE9-A603-42287ABBA767Q37965706-82146C91-9796-4889-ABF9-75C09277596FQ37974113-58891603-2ABF-4A74-B11F-94A8646E48BAQ37998136-D8EA4C00-3863-4E78-BCC1-261A489CF653Q38087695-035BCA59-8BE0-4E08-B59A-7DB42FF8C13DQ38346846-6D7D90D1-614E-46EC-B9CA-3C14E0665958Q38420688-C2A9C5AE-697C-4D23-8663-22DEC55571F2Q39476375-866DBBDE-DDF2-4B44-9DEF-13D60ECCD882Q39508318-C3FCB9BA-AA9C-412B-8594-7C528827D9A0Q39668365-A9DD8B4A-82C0-4BEE-AF42-71B001AEBED0Q42694829-E80C99B2-7E24-4268-A48B-62184003C0BFQ43923927-DBE16948-41D6-41BD-B3EF-E9E5D8437834Q45976136-8D7E4AB7-29C8-4C53-8CC0-86C15379FEBDQ46058619-C8400025-D48E-47C4-920F-792820FEBCC9Q47267937-45E5B072-C9EB-4076-9D54-E7F2A75A5C0AQ47313037-41EF0917-0800-4B31-944B-C78B469DB049Q47592224-7ACA3046-46CA-4A64-AB2B-50ED930747DBQ47990931-AA9C8744-BD6A-436E-AF60-7792DB9010B1Q48010621-86D486B3-39AF-47DA-AED5-F1FFA464DB09Q50279562-CB4A627A-B6B8-4A73-A58E-7E5132F83929Q51630491-84E7542C-6305-4746-8E92-6F1CB508CF9DQ53285942-36E850CA-EA86-4012-95D6-0660656A0536Q58752746-57A4C219-3E4E-4717-A64D-9F1CA4FF6CB7
P2860
Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Predictions of metabolic drug- ...... ith ketoconazole or verapamil.
@en
Predictions of metabolic drug- ...... ith ketoconazole or verapamil.
@nl
type
label
Predictions of metabolic drug- ...... ith ketoconazole or verapamil.
@en
Predictions of metabolic drug- ...... ith ketoconazole or verapamil.
@nl
prefLabel
Predictions of metabolic drug- ...... ith ketoconazole or verapamil.
@en
Predictions of metabolic drug- ...... ith ketoconazole or verapamil.
@nl
P2093
P2860
P1476
Predictions of metabolic drug- ...... with ketoconazole or verapamil
@en
P2093
Cedric Vinson
Fanny Cazade
François Bouzom
Marylore Chenel
Nathalie Perdaems
Sarah Whalley
P2860
P304
P356
10.2165/11318130-000000000-00000
P577
2010-04-01T00:00:00Z
P6179
1007590190